Cai Jing Wang·2026-01-28 05:19Core Viewpoint - The company expects to achieve an annual revenue of 1.04 billion to 1.08 billion yuan in 2025, representing a year-on-year growth of 22.88% to 27.61% [1] - The company anticipates a net profit attributable to shareholders of 24.5 million to 29 million yuan for the same period, marking a turnaround from losses in the previous year [1] Financial Performance - The projected revenue for 2025 is between 1.04 billion and 1.08 billion yuan, indicating a significant increase compared to the previous year [1] - The expected net profit for 2025 is between 24.5 million and 29 million yuan, which signifies a recovery from previous losses [1] Strategic Initiatives - The company continues to focus on innovation as its core strategy while emphasizing the importance of commercialization [1] - The revenue from the first quadrivalent meningococcal vaccine, Manhaixin, is experiencing sustained growth [1] - The company is actively pursuing cost reduction and efficiency improvement, leading to effective expense management [1] Operational Efficiency - The company has optimized production and sales coordination, resulting in an improvement in gross profit margin [1] - Overall profitability has significantly improved, achieving a net profit attributable to shareholders during the reporting period [1]